# Merck licenses a KRAS G12D inhibitor for $400M upfront

> **Open Intelligence Dossier** · First detected: 2026-09-28 22:00 UTC · Category: Business

## Executive Summary
Merck has entered a multi-billion dollar agreement with China's SciBrunch Therapeutics to develop a preclinical KRAS G12D inhibitor.

## Intelligence Brief
Merck has entered into an exclusive global license agreement with SciBrunch Therapeutics to gain the rights to a preclinical KRAS G12D (ON) inhibitor known as SPR2015. According to reports from Business Wire and Endpoints News, the financial structure of the deal includes an upfront payment of $400 million. The total value of the partnership could reach up to $2.13 billion, as detailed in coverage by biospace.com and Reuters. The agreement focuses on the development of SPR2015, which is described as an investigational oral inhibitor targeting the KRAS G12D mutation. Multiple industry outlets are tracking the deal, with Fierce Biotech and Reuters highlighting the significant financial commitment and the strategic nature of the partnership. Biospace.com specifically emphasizes the preclinical status of the inhibitor.


The reporting across these sources underscores the scale of the transaction, consistently citing the $2.13 billion potential value. Business Wire provides the specific technical designation of the drug, identifying it as an oral KRAS G12D (ON) inhibitor, which provides a clearer picture of the pharmaceutical target involved in this license. This deal occurs within a broader industry trend where United States drugmakers are increasingly looking toward China for licensing agreements. Reuters reports that this move by Merck is part of a wider shift of US-based pharmaceutical companies seeking innovative assets from Chinese biotech firms. The KRAS G12D inhibitor represents a specific target in cancer research, and by licensing SPR2015, Merck is expanding its portfolio of investigational therapies. This context suggests a strategic effort to acquire early-stage assets from international partners to fuel future oncology pipelines.


Looking forward, the focus will remain on the progress of SPR2015 as it moves from its current preclinical stage toward further development. The total payout of $2.13 billion is contingent on the success of the drug, though the immediate $400 million upfront payment has already been established. Observers will be monitoring whether other US drugmakers follow this pattern of seeking licensing deals in China, as indicated by the general trend reported by Reuters. The trajectory of the investigational oral inhibitor will determine if Merck realizes the full potential of the agreement with SciBrunch Therapeutics.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| Reuters | US drugmakers turn to China for licensing deals | [Source Link](https://news.google.com/rss/articles/CBMimAFBVV95cUxQWkJGbFUwTzg3ZWQ5OUxVcjR0MzN0NXhSRmk3Ukh4RFFkRkF3bFFKOGMtQzZ5WGVYNUlNSmE1Y0pKa01mSHp4ZWdqT0Q0Nkh1ZGl3cHZuZlNVang0aHEyeENsVGdfdDhOSmY5aE1DNlVPdWloQm5Gb182WmZrallZYjI5NDdQbVNENmQwVnZGWmhMMjJZQ09xWQ?oc=5) |
| biospace.com | Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitor | [Source Link](https://news.google.com/rss/articles/CBMiwAFBVV95cUxQU2dkNG5aektCUnhDSWdWV21kQnFZQTlVWkF5cjlVa3RnVE9aU1dRZXF1dE1XZVJWcWx2VUZIcXptR2Fmd20xbGVaSTNSU2NNS0NMc1p1bEttREVtdktCNk1zVUZJcXNERnFLeTRBUkQ4dWhQREdmY05OUFd5STdIWVhjY2JKcjg5YUhKLUk1VTI2cVdMcXNJUE9LeVZHMTBKR2FfamI2akJ4LTFkUUEwTXB6S2k5RXJVak15SG9Uc2M?oc=5) |
| Business Wire | Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor | [Source Link](https://news.google.com/rss/articles/CBMiogJBVV95cUxNTF93RVBSRGNnVEt3QVlNTFVwUlh6NzJzZkJTWUcwTW1FNE91cW5JVVNaREpDNURPTXhKSjgyeEg3ZW9iYnBzWUUtQU1yWmRPSnphRHJnOTJ6ZWdRSms5T05jaTBySzFsS0wzeHp3YUw2M21xQTB5M0hfcEZDT1pVSWF1Zk9mTW1PQUl1S042djUyclltTThjdjVsYm9IR1VaMUF5SGc5b1lWcVU2cDFuQ2ZaQ1o0M3lFRVB1UUY2Y1hWVHpuUlM2S2l6NHRYQkdtSjM1eTUxUVZfY1VUTlNyVDRWajJVMjU0ZUc0WW9YemliSTlyX3dVOGppbk5FYUNWRUdpYjFwNzU3NVdiSFJTb3FyRFVyVzBZb2dRdTY3WU5UZw?oc=5) |
| Fierce Biotech | Merck pens $2.1B deal with China’s SciBrunch to chase KRAS G12D | [Source Link](https://news.google.com/rss/articles/CBMilAFBVV95cUxOc1U3SFFCbndmc3JNdVRsN3h5ZE1LX3J0WnZJaDAzbm00VHhaX3oxdUlBSzBEZmlYa2JkOGNRQnhaVTRKdFhNUkVqclY1Q3phMnJ4OUswdDVEU3pzcDdjZ2pFTjkxeFRXZDJPcllmREM1OTRaaDM0UU1KRmoyZGUzMG5RWktnTi1XOURNajZqaTJkbzdR?oc=5) |
| Reuters | Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion | [Source Link](https://news.google.com/rss/articles/CBMitgFBVV95cUxQNDdBQWp0eXhySGlJdTloSFcwMVk1WmY1NzVlZldsRDZRTjRRdy0zTHVCbXU5QjRlSWdFWmI2OGNXNmN6SHp2dF9oOEItN1E2dl9kSnZjZVYwT096T1V0aUpvT0pzX29aWVhILVBLMDdZMkRQX2VsZHBrRUJuT3phY1MzQ2Rlcy12OEZWTm9XWG12YmZDVkI1cU1ObWtzNzJOcEN1MklZZ2dQWWxMRGJMQThLZFdFZw?oc=5) |
| Endpoints News | Merck licenses a KRAS G12D inhibitor for $400M upfront | [Source Link](https://news.google.com/rss/articles/CBMigwFBVV95cUxOb0JoTVRGczZyR2hmUW5yN1E4a0ZNaDE0cnhLRDVZeGU1SmMwYmYyYmI4Mkd1TEQ4Y3pBUWNTSUJqSVBzcFlXbjRjT3U2bUlyVGVMeWpKSnJHODFlOEdFWlBqSlJxM25KcjhkWE1GNThOYjB5cjVxTTdqcUxXbmpDbGgzMA?oc=5) |

---
*Canonical Source: https://pulse.byoaiapps.com/trend/2026-09-28/merck-licenses-a-kras-g12d-inhibitor-for-400m-upfront*
